Alzheimer's & dementia (Amsterdam, Netherlands) · 2026
Associations among mild behavioral impairment, cognition, and brain pathology in preclinical autosomal dominant Alzheimer's disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tristão-Pereira Catarina, Vasquez Daniel, Alcina Jorge, Baena Ana, Aguillon David, Ospina Lopera Paula, Londono Natalia, Ramos Claudia, Martinez Lusiana, Alvarez Sergio, Vidal Monica, Gonzalez Isabela, Malotaux Vincent, He Bing, Giudicessi Averi, Ramirez-Gomez Liliana, Gatchel Jennifer, Ismail Zahinoor, Quiroz Yakeel T
Аннотация
INTRODUCTION: The Mild Behavioral Impairment Checklist (MBI-C) captures neuropsychiatric symptoms in individuals at risk of dementia. In this study, we examined MBI-C scores in autosomal dominant Alzheimer's disease (ADAD).
METHODS: We included 83 cognitively unimpaired presenilin-1 E280A mutation carriers and 114 non-carriers with MBI-C, obfjective cognition, and subjective cognitive decline (SCD) assessments. Study sub-samples underwent neuroimaging to assess Alzheimer's disease (AD) pathology and neurodegeneration.
RESULTS: MBI-C total scores were greater in carriers than non-carriers (r rb = 0.19 [95% confidence interval (CI) 0.05, 0.31], P = 0.009), driven by impulse dyscontrol symptoms. Elevated MBI-C scores were associated with higher study partner-reported SCD scores (β = 0.28 [95% CI 0.07, 0.050], P = 0.008) and with greater neocortical amyloid beta (β = 0.46 [95% CI 0.17, 0.075], P = 0.003) among carriers.
DISCUSSION: Our study reveals that mild behavioral impairment symptoms may emerge before cognitive decline in ADAD and supports the MBI-C as a tool for detecting early behavioral changes linked to AD pathology and identifying at-risk individuals for clinical trials and early intervention.
METHODS: We included 83 cognitively unimpaired presenilin-1 E280A mutation carriers and 114 non-carriers with MBI-C, obfjective cognition, and subjective cognitive decline (SCD) assessments. Study sub-samples underwent neuroimaging to assess Alzheimer's disease (AD) pathology and neurodegeneration.
RESULTS: MBI-C total scores were greater in carriers than non-carriers (r rb = 0.19 [95% confidence interval (CI) 0.05, 0.31], P = 0.009), driven by impulse dyscontrol symptoms. Elevated MBI-C scores were associated with higher study partner-reported SCD scores (β = 0.28 [95% CI 0.07, 0.050], P = 0.008) and with greater neocortical amyloid beta (β = 0.46 [95% CI 0.17, 0.075], P = 0.003) among carriers.
DISCUSSION: Our study reveals that mild behavioral impairment symptoms may emerge before cognitive decline in ADAD and supports the MBI-C as a tool for detecting early behavioral changes linked to AD pathology and identifying at-risk individuals for clinical trials and early intervention.